pharmaceutical investing AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
pharmaceutical investing AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® Subcutaneous Induction in Patients with Crohn's Disease
pharmaceutical investing AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
pharmaceutical investing U.S. Food and Drug Administration Approves Combination Treatment of VENCLEXTA® and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia
pharmaceutical investing Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
pharmaceutical investing AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Adults and Adolescents With Vitiligo
pharmaceutical investing AbbVie Launches Love in Mind to Spotlight the Emotional Impact of Migraine on Romantic Relationships
pharmaceutical investing Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
pharmaceutical investing AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
pharmaceutical investing AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
pharmaceutical investing AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
QIMC Completes 711 Metre Discovery Hole DDH-26-01 at West-Advocate, Nova Scotia: Hydrogen System Confirmed at Depth
CORRECTION FROM SOURCE: Allied Critical Metals Further Highlights Rapid Payback, Capital Efficiency and Infrastructure from Borralha PEA
